Vertex Pharmaceuticals company profile
Company profile
Vertex Pharmaceuticals has 6,400 employees and is headquartered in Boston, United States.
Sales reach patients in the United States, Europe and other countries, with the United States accounting for 62.9% of revenue, Europe for 28.8% and the rest of the world for 8.3%. The biotechnology company offers cystic fibrosis medicines such as TRIKAFTA/KAFTRIO, ORKAMBI and KALYDECO, as well as CASGEVY for sickle cell disease and transfusion dependent beta thalassemia, and JOURNAVX for acute pain in adults. Its pipeline includes candidates for APOL1-mediated kidney disease, type 1 diabetes and myotonic dystrophy type 1. Customers include specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals and clinics.
In the fiscal year ended December 2025, revenue rose 8.9% to $12.0 billion and net income reached $4.0 billion. The company had 6,400 employees at year end and is headquartered in Boston, Massachusetts, where it was founded in 1989.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 50 Northern Avenue, 02210, Boston
- Employees
- 6,400
- Chief executive
- Reshma Kewalramani
- Founded
- 1989
- Fiscal year
- January - December
- Listing
- VRTX · NASDAQ
- Indices
- Nasdaq 100S&P 500
- Currency
- USD
- ISIN
- US92532F1003
- Website
- vrtx.com
Vertex Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Vertex PharmaceuticalsVRTX | United States | $137.94B | 6,400 | 37.8% | 35.0 |
| Regeneron PharmaceuticalsREGN | United States | $98.84B | 15,410 | 30.4% | 21.1 |
| ModernaMRNA | United States | $90.38B | 4,700 | -80.8% | — |
| argenxARGX | United States | $60.37B | 1,863 | 31.9% | 33.3 |
| BeOne MedicinesONC | United States | $47.58B | 12,000 | 17.8% | 53.4 |
| Royalty PharmaRPRX | United States | $39.85B | 100 | 64.4% | 45.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
